Gracell Biotechnologies Inc. Overview
Pro stress-test →Gracell Biotechnologies is a clinical-stage biopharmaceutical company that primarily discovers and develops cell therapies for the treatment of cancer. The company leverages pioneering FasTCAR and TruUCAR technology platforms to create a robust clinical-stage pipeline of autologous and allogeneic product candidates, addressing significant challenges in conventional CAR-T therapies such as lengthy manufacturing times, suboptimal production quality, high costs, and lack of effective therapies for solid tumors.
Strategic Profile
Pro stress-test →GC012F, an autologous CAR-T candidate utilizing the proprietary FasTCAR next-day manufacturing platform, has shown promise in treating multiple myeloma and other hematological cancers. The company was acquired by AstraZeneca, transitioning from independent clinical-stage developer to part of a major pharmaceutical conglomerate's oncology portfolio. As of July 2026, the company is in transition following its acquisition completion.
Competitive Landscape
Pro stress-test →Gracell competes in the CAR-T immunotherapy space against established programs from Juno Therapeutics (Celgene/Bristol Myers Squibb), Gilead Sciences (Kite Pharma), CITIC Pharma (domestic competitor), and emerging allogeneic CAR-T developers. Its differentiation rests on FasTCAR next-day manufacturing and TruUCAR allogeneic platform, addressing speed and cost inefficiencies of conventional approaches. Post-AstraZeneca acquisition, competitive positioning shifts toward internal pipeline integration rather than standalone commercial development.
Industry Context
Gracell Biotechnologies Inc. operates in CAR-T cell immunotherapy.
Key facts
Founded: 2017 · Headquarters: Suzhou, China · Employees: Unknown · Revenue: Pre-revenue clinical-stage company · Market cap: Approximately $990M as of February 2024 (pre-delisting); N/A post-acquisition